E
Ellison Themeles
Researcher at Population Health Research Institute
Publications - 21
Citations - 13649
Ellison Themeles is an academic researcher from Population Health Research Institute. The author has contributed to research in topics: Stroke & Dabigatran. The author has an hindex of 14, co-authored 21 publications receiving 12284 citations. Previous affiliations of Ellison Themeles include University of British Columbia & Goethe University Frankfurt.
Papers
More filters
Journal ArticleDOI
Dabigatran versus warfarin in patients with atrial fibrillation
Stuart J. Connolly,Michael D. Ezekowitz,John W. Eikelboom,Jonas Oldgren,Amit Parekh,Janice Pogue,Paul A. Reilly,Ellison Themeles,Jeanne Varrone,Susan Wang,Marco Alings,Denis Xavier,Jun Zhu,Rafael Diaz,Basil S. Lewis,Harald Darius,Hans-Christoph Diener,Campbell D. Joyner,Lars Wallentin +18 more
TL;DR: In patients with atrial fibrillation, dabigatran given at a dose of 110 mg was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of major hemorrhage.
Journal ArticleDOI
Subclinical Atrial Fibrillation and the Risk of Stroke
Jeff S. Healey,Stuart J. Connolly,Michael R. Gold,Carsten W. Israel,Isabelle C. Van Gelder,Alessandro Capucci,Chu-Pak Lau,Eric Fain,Sean Yang,Christophe Bailleul,Carlos A. Morillo,Mark A. Carlson,Ellison Themeles,Elizabeth S. Kaufman,Stefan H. Hohnloser +14 more
TL;DR: Subclinical atrial tachyarrhythmias, without clinical atrial fibrillation, occurred frequently in patients with pacemakers and were associated with a significantly increased risk of ischemic stroke or systemic embolism.
Journal ArticleDOI
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source
Robert G. Hart,Mukul Sharma,Hardi Mundl,Scott E. Kasner,Shrikant I. Bangdiwala,Scott D. Berkowitz,Balakumar Swaminathan,Pablo M. Lavados,Yongjun Wang,Yilong Wang,Antonio Dávalos,Nikolay Shamalov,Robert Mikulik,Luís Cunha,Arne Lindgren,Antonio Arauz,Wilfried Lang,Anna Członkowska,Jens Eckstein,Rubens José Gagliardi,Pierre Amarenco,Sebastian F. Ameriso,Turgut Tatlisumak,Roland Veltkamp,Graeme J. Hankey,Danilo Toni,Daniel Bereczki,Shinichiro Uchiyama,George Ntaios,Byung-Woo Yoon,Raf Brouns,Matthias Endres,K Muir,Natan M. Bornstein,Şerefnur Öztürk,Martin O'Donnell,Matthys M. De Vries Basson,Guillaume Paré,Calin Pater,Bodo Kirsch,Patrick Sheridan,Gary Peters,Jeffrey I. Weitz,W. Frank Peacock,Ashkan Shoamanesh,Oscar R. Benavente,Campbell D. Joyner,Ellison Themeles,Stuart J. Connolly +48 more
TL;DR: Rivaroxaban was not superior to aspirin with regard to the prevention of recurrent stroke after an initial embolic stroke of undetermined source and was associated with a higher risk of bleeding.
Journal ArticleDOI
Periprocedural Bleeding and Thromboembolic Events With Dabigatran Compared With Warfarin Results From the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial
Jeff S. Healey,John W. Eikelboom,James D. Douketis,Lars Wallentin,Jonas Oldgren,Sean Yang,Ellison Themeles,Hein Heidbuchel,Alvaro Avezum,Paul A. Reilly,Stuart J. Connolly,Salim Yusuf,Michael D. Ezekowitz +12 more
TL;DR: In this article, the periprocedural bleeding risk of patients in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial treated with dabigatran and warfarin was compared.
Journal ArticleDOI
Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran
Michael D. Ezekowitz,Stuart J. Connolly,Amit Parekh,Paul A. Reilly,Jeanne Varrone,Susan Wang,Jonas Oldgren,Ellison Themeles,Lars Wallentin,Salim Yusuf +9 more
TL;DR: The RE-LY trial is unique because it includes equal numbers of VKA-experienced and naive patients and evaluates 2 different dosages of dabigatran, which may allow tailoring of dosing to individual patient needs, and the worldwide site distribution and broad range of stroke risk further increase the general applicability.